Mutations in CCAAT/enhancer binding protein alpha (CEBPA) 
Abstract
Mutations in CCAAT/enhancer binding protein alpha (CEBPA) are seen in 5 
Introduction
Mutations in the transcription factor CCAAT/enhancer binding protein alpha (CEBPA) are found in 5-14% of acute myeloid leukemia (AML). [1] [2] [3] [4] [5] [6] [7] [8] [9] CEBPA mutations have been associated with a relatively favorable outcome, and have therefore gained interest as a prognostic marker. [4] [5] [6] 10 While variable sequence variations have been described, two prototypical classes of mutations are most frequent. N-terminal mutations are located between the major translational start codon and a second ATG
in the same open reading frame. These mutations introduce a premature stop of translation of the p42 CEBPA protein while preserving translation of a p30 isoform that has been reported to inhibit the function of full length protein. 2 Mutations in the C-terminal basic leucine zipper (bZIP) region, in contrast, are in-frame, and may impair DNA binding and/or homo-and heterodimerization. 8 The remaining mutations are mostly found between the N-terminus and bZIP region.
11
Most CEBPA mutant AMLs exhibit two mutations, which most frequently involves a combination of an N-terminal and a bZIP gene mutation. 7, 8, 11, 12 In AMLs with two CEBPA mutations, the mutations are typically on different alleles. 11 Hence, in these cases no wild type CEBPA protein is expressed. A similar condition is found in AMLs carrying a homozygous CEBPA mutation. 13 However, there are also AMLs that only show one single heterozygous mutation, and thus retain expression of a wild type allele. 7, 11, 12 To obtain better insight into the distribution of the various types of CEBPA 
Statistical analysis
Survival was estimated according to the method by Kaplan and Meier. The log rank test was used to assess statistical significance. Multivariable analysis was performed using Cox's proportional hazards models. Definitions of outcome parameters and cytogenetic risk groups have been described. 15 Further details are given in Supplementary Materials & Methods.
Gene expression profiling analysis
Gene expression profiles were obtained using Affymetrix (Santa Clara, CA)
HGU133Plus2.0 GeneChips. Details on data processing and analysis are given in Supplementary Materials & Methods.
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Results and discussion
In a cohort of 598 cases of adult de novo AML we identified 65 cases with an aberrant profile in at least one of the three investigated amplicons of the CEBPA coding sequence ( Figure 1A-B) . The presence of a CEBPA sequence variation was confirmed by nucleotide sequencing. Cases that only carried an insertion polymorphism 16, 17 or variation(s) that did not lead to amino acid changes were considered wild type. Two additional specimens were not considered in further analysis because they carried in-frame variations of unknown significance in the Nterminus (Table S1 ). As a result, 41/598 unambiguous CEBPA mut AML cases (6.9%)
were considered. These included 13 CEBPA single-mut cases and 28 CEBPA double-mut cases. Four of the CEBPA double-mut cases carried homozygous mutations whereas the remaining 24 cases showed 2 heterozygous mutations (Table S1 ). Additional screening of the remaining 547 AML cases using a combination of agarose gel analysis and nucleotide sequencing as described 6 did not reveal mutations that had been missed by dHPLC. Figure 1C, S1 ). In line with this, we were able to derive a specific 21-probe set classifier for CEBPA double-mut AMLs within the entire AML cohort with a cross-validated sensitivity of 100% (specificity 98%) (Table S3) . In further support, unsupervised analysis of the expression data derived from the CEBPA mut subset indicated an underlying variability in gene expression that correlated with either double or single mutation status ( Figure S2 ).
We next assessed how these differences between CEBPA double-mut and CEBPA single-mut related to clinical outcome. In line with previous data, overall survival and event-free survival were significantly better for CEBPA mut cases compared to cases with wild type CEBPA (CEBPA wt ) ( Figure 1D and not shown University Hospital, Mainz, Germany) who provided AML samples. We thank Sonja van der Poel for help with dHPLC analysis. We also thank our colleagues from the bone marrow transplantation group and molecular diagnostics group in the department of Hematology of Erasmus University Medical Center for storage of samples and molecular analysis, respectively. Table S2 for probe set information). Intensity values (log2) were mean centered over the cohort of 524 AML cases and for visualization purposes the genes were hierarchically clustered (Euclidian distance, average linkage). Cells represent relative log2 expression values, and have been color coded on a scale ranging from bright Figure S4 .
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